There are 2789 resources available
Q&A and live discussion
Presenter: Christophe Massard
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Invited Discussant 513O and 514O
Presenter: Elena Garralda
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Elena Garralda
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
Invited Discussant LBA11 and 117O
Presenter: Antonio Llombart Cussac
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Antonio Llombart Cussac
Session: Proffered Paper session - Breast cancer, early stage
Resources:
Slides
Webcast
LBA66 - Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial
Presenter: Nicolas Girard
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA42 - COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC
Presenter: Alexandre Martinez-Marti
Session: Proffered Paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
LBA32 - Principal results of the EORTC-1508 trial: A phase II randomised, multicentre study of bevacizumab vs atezolizumab and bevacizumab with acetylsalicylic acid or placebo in recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma
Presenter: Susana Banerjee
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
721O - Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study
Presenter: Domenica Lorusso
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
722O - Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
Presenter: Shibani Nicum
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast